News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ) to Pay $1 Billion to Settle Risperdal Marketing Probe


1/6/2012 8:07:41 AM

Johnson & Johnson will pay more than $1 billion in civil and criminal penalties to the federal government and individual states to settle an investigation into the marketing practices of its anti-psychotic drug Risperdal, Bloomberg News Service reported Thursday. The figure would be in line with what Eli Lilly & Co. paid three years ago to settle claims that it marketed a similar anti-psychotic drug, Zyprexa, for illnesses that weren’t approved by the U.S. Food and Drug Administration. “These pharmaceutical companies are going to be running, not walking, to the settlement table,” Patrick Burns, spokesman for Taxpayers Against Fraud, a Washington, D.C., consumer group, told New Jersey Press Media. “The numbers are going up very rapidly.”

Read at Courier Post Online
Read at BusinessWeek
Read at News Release
Read at App.com
Read at Boston Globe


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES